Cargando…

Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody

Recently, systemic administration of a human monoclonal antibody directed against cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on circulating T cells in patients with chronic lymphocytic leukaemia (CLL) has been considered. Also, CLL cells have been shown to express CTLA-4, increas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciszak, Lidia, Frydecka, Irena, Wolowiec, Dariusz, Szteblich, Aleksandra, Kosmaczewska, Agata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844645/ https://www.ncbi.nlm.nih.gov/pubmed/26490985 http://dx.doi.org/10.1007/s13277-015-4217-1

Ejemplares similares

CTLA-4 affects expression of key cell cycle regulators of G0/G1 phase in neoplastic lymphocytes from patients with chronic lymphocytic leukaemia
por: Ciszak, Lidia, et al.
Publicado: (2015)

BTLA Expression in CLL: Epigenetic Regulation and Impact on CLL B Cell Proliferation and Ability to IL-4 Production
por: Karabon, Lidia, et al.
Publicado: (2021)

Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia
por: Frydecka, I, et al.
Publicado: (2004)

Dysregulated Expression of Both the Costimulatory CD28 and Inhibitory CTLA-4 Molecules in PB T Cells of Advanced Cervical Cancer Patients Suggests Systemic Immunosuppression Related to Disease Progression
por: Kosmaczewska, Agata, et al.
Publicado: (2011)

Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients
por: Karabon, L., et al.
Publicado: (2020)

Alterations in Both the Activatory and Inhibitory Potential of Peripheral Blood CD4+ T Cells in Rheumatoid Arthritis Patients Correlate with Disease Progression
por: Kosmaczewska, Agata, et al.
Publicado: (2013)

Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors
por: Kulikowska de Nałęcz, Anna, et al.
Publicado: (2023)

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016)

Exogenous IL-2 Controls the Balance in Th1, Th17, and Treg Cell Distribution in Patients with Progressive Rheumatoid Arthritis Treated with TNF-Alpha Inhibitors
por: Kosmaczewska, Agata, et al.
Publicado: (2014)

Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL
por: Yano, Max, et al.
Publicado: (2022)

Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvement
por: Kosmaczewska, Agata, et al.
Publicado: (2013)

Imbalance in PB IL-17-Secreting and Regulatory Cells in Pars Planitis Is Associated with Dysregulation of IFN-γ-Secreting Cells, Especially in Patients with Clinical Complications
por: Kosmaczewska, Agata, et al.
Publicado: (2020)

The Mysterious Actor—γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL)
por: Zarobkiewicz, Michał K., et al.
Publicado: (2022)

The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
por: Van Dyke, Daniel L., et al.
Publicado: (2016)

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
por: Heinzerling, Lucie, et al.
Publicado: (2016)

Variations in Suppressor Molecule CTLA-4 Gene Are Related to Susceptibility to Multiple Myeloma in a Polish Population
por: Karabon, Lidia, et al.
Publicado: (2011)

Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients
por: Kulikowska de Nałęcz, Anna, et al.
Publicado: (2021)

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2021)

Not all lymphoid aggregates in chronic lymphocytic leukemia (CLL) patients are due to CLL!
por: Mahapatra, Lily, et al.
Publicado: (2021)

Pharmacological targeting of eIF4E in primary CLL lymphocytes
por: Martinez-Marignac, V, et al.
Publicado: (2013)

Adaptive and Innate Cytotoxic Effectors in Chronic Lymphocytic Leukaemia (CLL) Subjects with Stable Disease
por: Rubino, Valentina, et al.
Publicado: (2023)

CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma
por: Hoffmann, Friederike, et al.
Publicado: (2023)

CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
por: Pawlak-Adamska, Edyta, et al.
Publicado: (2016)

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
por: Du, Xuexiang, et al.
Publicado: (2018)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

Role of CTLA4 in the Proliferation and Survival of Chronic Lymphocytic Leukemia
por: Mittal, Amit K., et al.
Publicado: (2013)

The effect of peripheral blood lymphocyte stimulation on zeta chain expression and IL-2 production in Hodgkin's disease
por: Frydecka, I, et al.
Publicado: (2001)

Peptide Blocking CTLA-4 and B7-1 Interaction
por: Podlesnykh, Stepan V., et al.
Publicado: (2021)

Erratum to: CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
por: Pawlak-Adamska, Edyta, et al.
Publicado: (2017)

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
por: Fietz, Simon, et al.
Publicado: (2020)

Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
por: Odetola, Oluwatobi, et al.
Publicado: (2023)

Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms
por: Berry, Andrew, et al.
Publicado: (2008)

Shielding the Vulnerable: A Multicentre Australian Rollout of Evusheld to Patients with Chronic Lymphocytic Leukaemia (CLL-SHIELD)
por: Whitechurch, Ashley, et al.
Publicado: (2022)

Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index
por: Wang, Yucai, et al.
Publicado: (2021)

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
por: Wada, Satoshi, et al.
Publicado: (2013)

Pitfalls of immunotherapy: lessons from a patient with CTLA-4 haploinsufficiency
por: Watson, Leisa Rebecca, et al.
Publicado: (2018)

The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial
por: Oscier, David, et al.
Publicado: (2016)

Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes
Publicado: (1992)

CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation
por: Lingel, Holger, et al.
Publicado: (2017)

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
por: Egle, Alexander, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j625lgrf0tache8m91hig63j71